Cassava Sciences, now Filana Therapeutics, reports developments around its biotechnology program for central nervous system disorders, with current focus on Tuberous Sclerosis Complex (TSC)-related epilepsy. Company updates center on simufilam, a proprietary investigational oral small molecule intended to modulate filamin A protein, including preclinical work, clinical-development planning, and publication of prior Phase 3 Alzheimer’s disease trial results.
Recurring news also covers financial results, cash-use updates, leadership and board changes, and legal or regulatory matters, including the closure of government inquiries and securities litigation updates. The completed name change and ticker transition are part of the company’s durable corporate-status history.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.